Why Does COVID-19 Vaccine Acceptance Rate Remain Low Among Patients with Chronic Diseases? Evidences from Public Hospitals of Ethiopia
Chala Daba,Lechisa Asefa,Hailu Lemma,Amanuel Atamo,Edosa Kebede,Mesfin Gebrehiwot
DOI: https://doi.org/10.2147/PPA.S362131
2022-05-27
Patient Preference and Adherence
Abstract:Chala Daba, 1, &ast Lechisa Asefa, 2 Hailu Lemma, 2 Amanuel Atamo, 1 Edosa Kebede, 3 Mesfin Gebrehiwot 1, &ast 1 Department of Environmental Health, College of Medicine and Health Sciences, Wollo University, Dessie, Ethiopia; 2 Department of Environmental Health, Institute of Health, Bule Hora University, Bule Hora, Ethiopia; 3 Department of Medical Laboratory, College of Medicine and Health Sciences, Ambo University, Ambo, Ethiopia &astThese authors contributed equally to this work Correspondence: Chala Daba, Email Background: Elders and patients with chronic diseases are more vulnerable to coronavirus disease 2019 (COVID-19) infection. In Ethiopia, these groups of people are given vaccination priorities amongst others. However, there is limited information on the acceptance of COVID-19 vaccine among patients with chronic diseases. Therefore, this study aimed to assess the acceptance of COVID-19 vaccine and associated factors among patients with chronic diseases visiting public hospitals in West Guji zone (Ethiopia). Methods and Materials: Facility-based cross-sectional study was employed among 408 chronic disease patients visiting two public hospitals in Ethiopia from September to October 2021. Data was collected using structured questionnaire. Multivariable logistic regression was computed to identify factors associated with acceptance of COVID-19 vaccine. Independent variables with p-value less than 0.05 were considered statistically significantly associated with the acceptance of COVID-19 vaccine. Results: The acceptance of COVID-19 vaccine among patients with chronic diseases was 39.5% (95% CI: 35– 44). Factors positively associated with the acceptance of COVID-19 vaccine were age ≥ 40 years (AOR = 2.84; 95% CI: 1.53– 5.28), urban residence (AOR = 0.6; 95% CI: 0.38– 0.95), having upper respiratory tract infection (AOR = 1.32; 95% CI: 1.03– 2.8), previous COVID-19 infection (AOR = 2.1; 95% CI: 1.22– 3.47), having health insurance (AOR = 2.55; 95% CI: 1.23– 5.28), those not drinking alcohol (AOR = 1.95; 95% CI: 1.24– 3.06), those not chewing Khat (AOR = 2.01; 95% CI: 1.27– 3.2), and having good knowledge (AOR = 1.55; 95% CI: 1.03– 2.87) and positive attitude (AOR = 2.05; 95% CI: 1.26– 3.33) towards the vaccine. Conclusion: The overall proportion of COVID-19 vaccine acceptance is low among patients with chronic diseases. Therefore, to improve the acceptance of COVID-19 vaccine, the government and health professionals should provide continuous health education. Keywords: COVID-19, vaccine acceptance, chronic disease, Ethiopia Coronavirus disease 2019 (COVID-19) is one of the viral diseases affecting human respiratory system. 1–3 It is transmitted mainly through respiratory droplets that are released from an infected person while sneezing, coughing, and talking. 4 As of 8 February 2022, it affected more than 398 million people and caused 5.7 million deaths globally. 5 In Africa, over 10.9 million cases and 241,723 deaths were reported as of 8 February, 2022. Similarly, till this period, there were 466,677 confirmed cases and 7373 deaths in Ethiopia. 6 Although the virus is infecting all age groups, elders and patients living with chronic diseases, such as hypertension, tuberculosis, cardiac disease, lung disease, cancer, and diabetes, are almost five times more likely to develop severe COVID-19 illnesses and deaths. 7,8 To curb the transmission of this pandemic, different prevention and control measures, including social distancing, wearing face masks, proper hand washing with soap, and staying at home, are being applied. 8,9 In spite of the implementation of different prevention and control methods, the transmission is not decreasing substantially. 10 Hence, development of other effective control method, particularly vaccination, is becoming a significant protective measure against COVID-19 transmission. 10–12 Accordingly, as of 28 September 2021, approximately 104 vaccines have been tested in human clinical trials, of which 46 in phase II and 35 in phase III clinical trials. 13 However, the acceptance of these vaccines varied from place to place. For instance, a study conducted in northeast Ethiopia by Berihun et al has reported about 59.4% acceptance of COVID-19 vaccine among patients with chronic diseases. 14 Other studies performed in northwest Ethiopia, Arab world, and France also reported an acceptance rate of 54.8% 17, 62.4%, 9 and 65.6%, 15 respectively. Higher acceptance rates were also indicated in China (91.3%) 19 and Indonesia (93.3%). 2 -Abstract Truncated-
medicine, general & internal